Peripheral targets in obesity treatment: A comprehensive update

Obesity Reviews

Volumn 15, Issue 6, 2014, Pages 487-503

  Chatzigeorgiou, A ^a,b   Kandaraki, E ^a   Papavassiliou, A G ^a   Koutsilieris, M ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Adipose tissue; Anti obesity drugs; Energy absorption; Energy expenditure

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; ACYLTRANSFERASE INHIBITOR; ANGIOGENESIS INHIBITOR; ANTIOBESITY AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR 1 ANTAGONIST; DIACYLGLYCEROL ACYLTRANSFERASE INHIBITOR; DIAZOXIDE; ESTERASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR AGONIST; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GROWTH HORMONE DERIVATIVE; METHIONINE; METHIONINE AMINOPETIDASE 2 INHIBITOR; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; MONOACYLGLYCEROL O ACYLTRANSFERASE INHIBITOR; PANCREATIC LIPASE INHIBITOR; SIRTUIN 1; SIRTUIN 1 ACTIVATOR; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; THYROID HORMONE RECEPTOR BETA AGONIST; UNCLASSIFIED DRUG; 2-ACYLGLYCEROL O-ACYLTRANSFERASE; ACYLTRANSFERASE; CARRIER PROTEIN; DIACYLGLYCEROL ACYLTRANSFERASE; ENZYME INHIBITOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PNLIP PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2; THYROID HORMONE RECEPTOR BETA; TRIACYLGLYCEROL LIPASE;

ADIPOSE TISSUE; ARTICLE; CALORIC RESTRICTION; CARDIOVASCULAR RISK; DIET; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; ENERGY ABSORPTION; ENERGY EXPENDITURE; EXERCISE; FAT INTAKE; FAT MASS; GLUCOSE TOLERANCE; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN SENSITIVITY; LIPID METABOLISM; METABOLIC SYNDROME X; MITOCHONDRIAL RESPIRATION; MULTICENTER STUDY (TOPIC); NONHUMAN; OBESITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; WEIGHT CONTROL; WEIGHT GAIN; WEIGHT REDUCTION; AGONISTS; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENERGY METABOLISM;

ACYLTRANSFERASES; ADIPOSE TISSUE; ANGIOGENESIS INHIBITORS; ANTI-OBESITY AGENTS; CARRIER PROTEINS; DIACYLGLYCEROL O-ACYLTRANSFERASE; ENERGY METABOLISM; ENZYME INHIBITORS; HUMANS; LIPASE; OBESITY; RECEPTORS, GLUCAGON; SODIUM-GLUCOSE TRANSPORTER 2; THYROID HORMONE RECEPTORS BETA;

EID: 84899648843     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12163     Document Type: Article

References (169)

1. Chatzigeorgiou A, Karalis KP, Bornstein SR, Chavakis T. Lymphocytes in obesity-related adipose tissue inflammation. Diabetologia 2012; 55: 2583-2592.
2. WHO. Obesity and overweight. Fact sheet No. 311. 2013. [WWW document]. URL http://www.who.int/mediacentre/factsheets/fs311/en/index.html (accessed February 2014).
3. Surmi BK, Hasty AH. Macrophage infiltration into adipose tissue: initiation, propagation and remodeling. Future Lipidol 2008; 3: 545-556.
4. Anderson EK, Gutierrez DA, Hasty AH. Adipose tissue recruitment of leukocytes. Curr Opin Lipidol 2010; 21: 172-177.
5. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
6. Wu H, Ghosh S, Perrard XD etal. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 2007; 115: 1029-1038.
7. Xu H, Barnes GT, Yang Q etal. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830.
8. Chatzigeorgiou A, Phieler J, Gebler J, Bornstein SR, Chavakis T. CD40L stimulates the crosstalk between adipocytes and inflammatory cells. Horm Metab Res 2013; 45: 741-747.
9. Phieler J, Chung KJ, Chatzigeorgiou A etal. The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance. J Immunol 2013; 191: 4367-4374.
10. Carr DB, Utzschneider KM, Hull RL etal. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004; 53: 2087-2094.
11. Fox CS, Massaro JM, Hoffmann U etal. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 39-48.
12. Kang JG, Park CY. Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J 2012; 36: 13-25.
13. Clandinin MT, Cheema S, Field CJ, Garg ML, Venkatraman J, Clandinin TR. Dietary fat: exogenous determination of membrane structure and cell function. FASEB J 1991; 5: 2761-2769.
14. Sims EA, Danforth E Jr, Horton ES, Bray GA, Glennon JA, Salans LB. Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm Res 1973; 29: 457-496.
15. Sims EA. Experimental obesity, dietary-induced thermogenesis, and their clinical implications. Clin Endocrinol Metab 1976; 5: 377-395.
16. Witkamp RF. Current and future drug targets in weight management. Pharm Res 2011; 28: 1792-1818.
17. Patsch R. Postprandial lipaemia. Baillieres Clin Endocrinol Metab 1987; 1: 551-561.
18. Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992; 55: 309S-313S.
19. Birari RB, Bhutani KK. Pancreatic lipase inhibitors from natural sources: unexplored potential. Drug Discov Today 2007; 12: 879-889.
20. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161.
21. FDA. FDA Drug Safety Communication: Completed safety review of Xenical/Alli (orlistat) and severe liver injury. 2010. [WWW document]. URL http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm213038.htm (accessed February 2014).
22. Kopelman P, Groot Gde H, Rissanen A etal. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring) 2010; 18: 108-115.
23. Kopelman P, Bryson A, Hickling R etal. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond) 2007; 31: 494-499.
24. Norgine. Norgine acquires cetilistat. 2009. [WWW document]. URL http://www.norgine.com/downloads/pr_archive/Norgine%20aquires%20cetilistat_2.pdf (accessed February 2014).
25. Halford JC. Obesity drugs in clinical development. Curr Opin Investig Drugs 2006; 7: 312-318.
26. Shi Y, Cheng D. Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism. Am J Physiol Endocrinol Metab 2009; 297: E10-E18.
27. Chen HC, Farese RV Jr. Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25: 482-486.
28. Cao J, Cheng L, Shi Y. Catalytic properties of MGAT3, a putative triacylglycerol synthase. J Lipid Res 2007; 48: 583-591.
29. Yen CL, Cheong ML, Grueter C etal. Deficiency of the intestinal enzyme acyl CoA:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding. Nat Med 2009; 15: 442-446.
30. Suzuki S, Ramos EJ, Goncalves CG, Chen C, Meguid MM. Changes in GI hormones and their effect on gastric emptying and transit times after Roux-en-Y gastric bypass in rat model. Surgery 2005; 138: 283-290.
31. Cheng D, Iqbal J, Devenny J etal. Acylation of acylglycerols by acyl coenzyme A:diacylglycerol acyltransferase 1 (DGAT1). Functional importance of DGAT1 in the intestinal fat absorption. J Biol Chem 2008; 283: 29802-29811.
32. Yamazaki T, Sasaki E, Kakinuma C, Yano T, Miura S, Ezaki O. Increased very low density lipoprotein secretion and gonadal fat mass in mice overexpressing liver DGAT1. J Biol Chem 2005; 280: 21506-21514.
33. Zhao G, Souers AJ, Voorbach M etal. Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. J Med Chem 2008; 51: 380-383.
34. Hussain MM, Rava P, Pan X etal. Microsomal triglyceride transfer protein in plasma and cellular lipid metabolism. Curr Opin Lipidol 2008; 19: 277-284.
35. Hussain MM, Bakillah A. New approaches to target microsomal triglyceride transfer protein. Curr Opin Lipidol 2008; 19: 572-578.
36. Spann NJ, Kang S, Li AC etal. Coordinate transcriptional repression of liver fatty acid-binding protein and microsomal triglyceride transfer protein blocks hepatic very low density lipoprotein secretion without hepatosteatosis. J Biol Chem 2006; 281: 33066-33077.
37. Chandler CE, Wilder DE, Pettini JL etal. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res 2003; 44: 1887-1901.
38. Wren JA, Ramudo AA, Campbell SL etal. Efficacy and safety of dirlotapide in the management of obese dogs evaluated in two placebo-controlled, masked clinical studies in North America. J Vet Pharmacol Ther 2007; 30(Suppl. 1): 81-89.
39. Li J, Bertinato P, Cheng H etal. Discovery of potent and orally active MTP inhibitors as potential anti-obesity agents. Bioorg Med Chem Lett 2006; 16: 3039-3042.
40. Drugs.com . Surface Logix achieves objectives with SLx-4090 in phase 2a clinical trial. 2008. [WWW document]. URL http://www.drugs.com/clinical_trials/surface-logix-achieves-objectives-slx-4090-phase-2a-clinical-trial-3277.html (accessed February 2014).
41. Tong W, Paradise E, Kim E etal. Clinical Investigations of SLx-4090 in Combination with Metformin in Type 2 Diabetics. 70th Scientific Sessions, American Diabetes Association. 2010; Abstract Number 651-P.
42. Van Gaal L, Vercruysse F, Wajs E, Xie J, Ways D, van Nueten L. JNJ-16269110, an enterically targeted microsomal triglyceride transfer protein inhibitor, lowers body weight in overweight/obese subjects. Obes Rev 2010; 11(Suppl. 1): 42.
43. Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009; 11: 79-88.
44. Goldenberg MM. Pharmaceutical approval update. P T 2013; 38: 443-445.
45. Kanwal A, Banerjee SK. SGLT inhibitors: a novel target for diabetes. Pharm Pat Anal 2013; 2: 77-91.
46. Squibb B-M. Prescribing FORXIGA®: clinical experience. 2013. [WWW document]. URL http://www.forxiga.eu/node/65 (accessed February 2014).
47. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 2013; 11: 43.
48. Nauck MA, Del Prato S, Meier JJ etal. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-2022.
49. Andrianesis V, Doupis J. The role of kidney in glucose homeostasis - SGLT2 inhibitors, a new approach in diabetes treatment. Expert Rev Clin Pharmacol 2013; 6: 519-539.
50. Bolinder J, Ljunggren O, Kullberg J etal. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020-1031.
51. Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring) 2012; 20: 1645-1652.
52. Abu-Elheiga L, Matzuk MM, Abo-Hashema KA, Wakil SJ. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 2001; 291: 2613-2616.
53. Clapham JC, Arch JR. Targeting thermogenesis and related pathways in anti-obesity drug discovery. Pharmacol Ther 2011; 131: 295-308.
54. Miyazaki M, Kim YC, Gray-Keller MP, Attie AD, Ntambi JM. The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1. J Biol Chem 2000; 275: 30132-30138.
55. Ntambi JM, Miyazaki M, Stoehr JP etal. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci U S A 2002; 99: 11482-11486.
56. Miyazaki M, Man WC, Ntambi JM. Targeted disruption of stearoyl-CoA desaturase1 gene in mice causes atrophy of sebaceous and meibomian glands and depletion of wax esters in the eyelid. J Nutr 2001; 131: 2260-2268.
57. Brown JM, Chung S, Sawyer JK etal. Inhibition of stearoyl-coenzyme A desaturase 1 dissociates insulin resistance and obesity from atherosclerosis. Circulation 2008; 118: 1467-1475.
58. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-1023.
59. Thuny F, Richet H, Casalta JP, Angelakis E, Habib G, Raoult D. Vancomycin treatment of infective endocarditis is linked with recently acquired obesity. PLoS ONE 2010; 5: e9074.
60. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1031.
61. Engelstoft MS, Egerod KL, Holst B, Schwartz TW. A gut feeling for obesity: 7TM sensors on enteroendocrine cells. Cell Metab 2008; 8: 447-449.
62. Tseng YH, Cypess AM, Kahn CR. Cellular bioenergetics as a target for obesity therapy. Nat Rev Drug Discov 2010; 9: 465-482.
63. Cypess AM, Kahn CR. Brown fat as a therapy for obesity and diabetes. Curr Opin Endocrinol Diabetes Obes 2010; 17: 143-149.
64. Betz MJ, Enerback S. Therapeutic prospects of metabolically active brown adipose tissue in humans. Front Endocrinol (Lausanne) 2011; 2: 86.
65. Baxter JD, Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 2009; 8: 308-320.
66. Joharapurkar AA, Dhote VV, Jain MR. Selective thyromimetics using receptor and tissue selectivity approaches: prospects for dyslipidemia. J Med Chem 2012; 55: 5649-5675.
67. Angelin B, Rudling M. Lipid lowering with thyroid hormone and thyromimetics. Curr Opin Lipidol 2010; 21: 499-506.
68. Shoemaker TJ, Kono T, Mariash CN, Evans-Molina C. Thyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs? Endocr Pract 2012; 18: 954-964.
69. Bryzgalova G, Effendic S, Khan A etal. Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141. J Steroid Biochem Mol Biol 2008; 111: 262-267.
70. Grover GJ, Mellstrom K, Ye L etal. Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci U S A 2003; 100: 10067-10072.
71. Villicev CM, Freitas FR, Aoki MS etal. Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats. J Endocrinol 2007; 193: 21-29.
72. Grover GJ, Egan DM, Sleph PG etal. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3, 5, 3'-triiodo-L-thyronine. Endocrinology 2004; 145: 1656-1661.
73. Tancevski I, Demetz E, Eller P. Sobetirome: a selective thyromimetic for the treatment of dyslipidemia. Recent Pat Cardiovasc Drug Discov 2011; 6: 16-19.
74. Berkenstam A, Kristensen J, Mellstrom K etal. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci U S A 2008; 105: 663-667.
75. Sangiao-Alvarellos S, Vazquez MJ, Varela L etal. Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion. Endocrinology 2009; 150: 4562-4574.
76. Valentino MA, Lin JE, Waldman SA. Central and peripheral molecular targets for antiobesity pharmacotherapy. Clin Pharmacol Ther 2010; 87: 652-662.
77. Tomlinson JW, Crabtree N, Clark PM etal. Low-dose growth hormone inhibits 11 beta-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity. J Clin Endocrinol Metab 2003; 88: 2113-2118.
78. Franco C, Andersson B, Lonn L, Bengtsson BA, Svensson J, Johannsson G. Growth hormone reduces inflammation in postmenopausal women with abdominal obesity: a 12-month, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007; 92: 2644-2647.
79. Bredella MA, Lin E, Brick DJ etal. Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial. Eur J Endocrinol 2012; 166: 601-611.
80. Albert SG, Haas MJ, Mooradian AD. The effects of recombinant human growth hormone (rhGH) supplementation on adipokines and C-reactive protein in obese subjects. Growth Horm IGF Res 2007; 17: 19-25.
81. Wamil M, Seckl JR. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov Today 2007; 12: 504-520.
82. Liu Y, Nakagawa Y, Wang Y etal. Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice. Diabetes 2003; 52: 1409-1416.
83. Livingstone DE, Jones GC, Smith K etal. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 2000; 141: 560-563.
84. Morton NM. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol 2010; 316: 154-164.
85. Morton NM, Paterson JM, Masuzaki H etal. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004; 53: 931-938.
86. Densmore VS, Morton NM, Mullins JJ, Seckl JR. 11 beta-hydroxysteroid dehydrogenase type 1 induction in the arcuate nucleus by high-fat feeding: a novel constraint to hyperphagia? Endocrinology 2006; 147: 4486-4495.
87. Dhanesha N, Joharapurkar A, Shah G etal. Inhibition of 11beta-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice. Clin Exp Pharmacol Physiol 2012; 39: 69-77.
88. Alberts P, Nilsson C, Selen G etal. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003; 144: 4755-4762.
89. Hermanowski-Vosatka A, Balkovec JM, Cheng K etal. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 2005; 202: 517-527.
90. Johansson L, Fotsch C, Bartberger MD etal. 2-Amino-1, 3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice. J Med Chem 2008; 51: 2933-2943.
91. Anagnostis P, Katsiki N, Adamidou F etal. 11Beta-hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? Metabolism 2013; 62: 21-33.
92. Deng C, Paoloni-Giacobino A, Kuehne F etal. Respective degree of expression of beta 1-, beta 2- and beta 3-adrenoceptors in human brown and white adipose tissues. Br J Pharmacol 1996; 118: 929-934.
93. Tan S, Curtis-Prior PB. Characterization of the beta-adrenoceptor of the adipose cell of the rat. Int J Obes 1983; 7: 409-414.
94. Arch JR, Ainsworth AT, Ellis RD etal. Treatment of obesity with thermogenic beta-adrenoceptor agonists: studies on BRL 26830A in rodents. Int J Obes 1984; 8(Suppl. 1): 1-11.
95. Arch JR, Ainsworth AT. Thermogenic and antiobesity activity of a novel beta-adrenoceptor agonist (BRL 26830A) in mice and rats. Am J Clin Nutr 1983; 38: 549-558.
96. Isidro ML, Cordido F. Drug treatment of obesity: established and emerging therapies. Mini Rev Med Chem 2009; 9: 664-673.
97. Collins S, Cao W, Robidoux J. Learning new tricks from old dogs: beta-adrenergic receptors teach new lessons on firing up adipose tissue metabolism. Mol Endocrinol 2004; 18: 2123-2131.
98. Larsen TM, Toubro S, van Baak MA etal. Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr 2002; 76: 780-788.
99. Redman LM, de Jonge L, Fang X etal. Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study. J Clin Endocrinol Metab 2007; 92: 527-531.
100. Alemzadeh R, Jacobs W, Pitukcheewanont P. Antiobesity effect of diazoxide in obese Zucker rats. Metabolism 1996; 45: 334-341.
101. Alemzadeh R, Slonim AE, Zdanowicz MM, Maturo J. Modification of insulin resistance by diazoxide in obese Zucker rats. Endocrinology 1993; 133: 705-712.
102. Due A, Flint A, Eriksen G etal. No effect of inhibition of insulin secretion by diazoxide on weight loss in hyperinsulinaemic obese subjects during an 8-week weight-loss diet. Diabetes Obes Metab 2007; 9: 566-574.
103. van Boekel G, Loves S, van Sorge A, Ruinemans-Koerts J, Rijnders T, de Boer H. Weight loss in obese men by caloric restriction and high-dose diazoxide-mediated insulin suppression. Diabetes Obes Metab 2008; 10: 1195-1203.
104. Lomb DJ, Laurent G, Haigis MC. Sirtuins regulate key aspects of lipid metabolism. Biochim Biophys Acta 2011; 1804: 1652-1657.
105. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschop MH. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A 2008; 105: 9793-9798.
106. Gillum MP, Kotas ME, Erion DM etal. SirT1 regulates adipose tissue inflammation. Diabetes 2011; 60: 3235-3245.
107. Lagouge M, Argmann C, Gerhart-Hines Z etal. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127: 1109-1122.
108. Bruckbauer A, Zemel MB, Thorpe T etal. Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr Metab (Lond) 2012; 9: 77.
109. Bemis JE, Vu CB, Xie R etal. Discovery of oxazolo[4, 5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators. Bioorg Med Chem Lett 2009; 19: 2350-2353.
110. Feige JN, Lagouge M, Canto C etal. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 2008; 8: 347-358.
111. Nogueiras R, Habegger KM, Chaudhary N etal. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev 2012; 92: 1479-1514.
112. Goh KP, Lee HY, Lau DP, Supaat W, Chan YH, Koh AF. Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. Int J Sport Nutr Exerc Metab 2013. [Epub ahead of print].
113. Timmers S, Konings E, Bilet L etal. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011; 14: 612-622.
114. Libri V, Brown AP, Gambarota G etal. A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS ONE 2013; 7: e51395.
115. Lijnen HR. Angiogenesis and obesity. Cardiovasc Res 2008; 78: 286-293.
116. Rupnick MA, Panigrahy D, Zhang CY etal. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A 2002; 99: 10730-10735.
117. Brakenhielm E, Cao R, Gao B etal. Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ Res 2004; 94: 1579-1588.
118. Kim YM, An JJ, Jin YJ etal. Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732. J Mol Endocrinol 2007; 38: 455-465.
119. Nishimura S, Manabe I, Nagasaki M etal. Adipogenesis in obesity requires close interplay between differentiating adipocytes, stromal cells, and blood vessels. Diabetes 2007; 56: 1517-1526.
120. Lijnen HR, Van Hoef B, Kemp D, Collen D. Inhibition of vascular endothelial growth factor receptor tyrosine kinases impairs adipose tissue development in mouse models of obesity. Biochim Biophys Acta 2007; 1770: 1369-1373.
121. Elias I, Franckhauser S, Ferre T etal. Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance. Diabetes 2012; 61: 1801-1813.
122. Sun K, Wernstedt Asterholm I, Kusminski CM etal. Dichotomous effects of VEGF-A on adipose tissue dysfunction. Proc Natl Acad Sci U S A 2012; 109: 5874-5879.
123. Tiwari A, Maiti P. TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders. Drug Discov Today 2009; 14: 523-530.
124. Pols TW, Noriega LG, Nomura M, Auwerx J, Schoonjans K. The bile acid membrane receptor TGR5: a valuable metabolic target. Dig Dis 2011; 29: 37-44.
125. Pols TW, Noriega LG, Nomura M, Auwerx J, Schoonjans K. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol 2011; 54: 1263-1272.
126. Thomas C, Gioiello A, Noriega L etal. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10: 167-177.
127. Watanabe M, Houten SM, Mataki C etal. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439: 484-489.
128. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008; 7: 678-693.
129. Rizzo G, Passeri D, De Franco F etal. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol Pharmacol 2010; 78: 617-630.
130. Pellicciari R, Gioiello A, Macchiarulo A etal. Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J Med Chem 2009; 52: 7958-7961.
131. George M, Rajaram M, Shanmugam E. New and emerging drug molecules against obesity. J Cardiovasc Pharmacol Ther 2013; 19: 65-76.
132. Hughes TE, Kim DD, Marjason J, Proietto J, Whitehead JP, Vath JE. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity (Silver Spring) 2013; 21: 1782-1788.
133. Lijnen HR, Frederix L, Van Hoef B. Fumagillin reduces adipose tissue formation in murine models of nutritionally induced obesity. Obesity (Silver Spring) 2010; 18: 2241-2246.
134. Nam DH, Lee MH, Kim JE etal. Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice. Endocrinology 2012; 153: 1387-1396.
135. Kim SP, Woolcott OO, Hsu IR etal. CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs. Am J Physiol Endocrinol Metab 2012; 302: E1261-E1268.
136. Lazary J, Juhasz G, Hunyady L, Bagdy G. Personalized medicine can pave the way for the safe use of CB(1) receptor antagonists. Trends Pharmacol Sci 2011; 32: 270-280.
137. Silvestri C, Di Marzo V. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Expert Opin Investig Drugs 2012; 21: 1309-1322.
138. Fulp A, Bortoff K, Seltzman H etal. Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity. J Med Chem 2012; 55: 2820-2834.
139. Klumpers LE, Fridberg M, de Kam ML etal. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. Br J Clin Pharmacol 2013; 76: 846-857.
140. Cinar R, Godlewski G, Liu J etal. Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides. Hepatology 2014; 59: 143-153.
141. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157.
142. Koliaki C, Doupis J. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther 2011; 2: 101-121.
143. Seino Y. Understanding the incretin effect. J Clin Endocrinol Metab 2011; 96: 934-935.
144. Deane AM, Nguyen NQ, Stevens JE etal. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010; 95: 215-221.
145. Williams DL, Baskin DG, Schwartz MW. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 2009; 150: 1680-1687.
146. Holst JJ, Schwartz TW, Lovgreen NA, Pedersen O, Beck-Nielsen H. Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity. Int J Obes 1983; 7: 529-538.
147. Madsbad S. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes Obes Metab 2014; 16: 9-21.
148. Muscelli E, Mari A, Casolaro A etal. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008; 57: 1340-1348.
149. Ranganath L, Norris F, Morgan L, Wright J, Marks V. Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids. Clin Sci (Lond) 1999; 96: 335-342.
150. Anini Y, Brubaker PL. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 2003; 52: 252-259.
151. Meneghini LF, Orozco-Beltran D, Khunti K etal. Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 3337-3353.
152. Amylin Pharmaceuticals I, Eli Lilly and Company. Lilly and Amylin mutually agree to end diabetes alliance and transition exenatide responsibility to Amylin. 2011. [WWW document]. URL https://investor.lilly.com/releasedetail2.cfm?ReleaseID=621647 (accessed February 2014).
153. Rosenstock J, Klaff LJ, Schwartz S etal. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010; 33: 1173-1175.
154. Dushay J, Gao C, Gopalakrishnan GS etal. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care 2011; 35: 4-11.
155. Kelly AS, Rudser KD, Nathan BM etal. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. JAMA Pediatr 2013; 167: 355-360.
156. Buse JB, Drucker DJ, Taylor KL etal. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010; 33: 1255-1261.
157. Astrup A, Carraro R, Finer N etal. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36: 843-854.
158. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2013. [Epub ahead of print].
159. Davies M, Speight J. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012; 14: 882-892.
160. Lean ME, Carraro R, Finer N etal. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond) 2013. [Epub ahead of print].
161. Davidson JA. Incretin-based therapies: focus on effects beyond glycemic control alone. Diabetes Ther 2013; 4: 221-238.
162. Torekov SS, Madsbad S, Holst JJ. Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. Obes Rev 2011; 12: 593-601.
163. Tschop MH, DiMarchi RD. Outstanding Scientific Achievement Award Lecture 2011: defeating diabesity: the case for personalized combinatorial therapies. Diabetes 2012; 61: 1309-1314.
164. Day JW, Ottaway N, Patterson JT etal. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 2009; 5: 749-757.
165. Dietrich MO, Horvath TL. Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. Nat Rev Drug Discov 2012; 11: 675-691.
166. Rueda-Clausen CF, Padwal RS, Sharma AM. New pharmacological approaches for obesity management. Nat Rev Endocrinol 2013; 9: 467-478.
167. Ling H, Lenz TL, Burns TL, Hilleman DE. Reducing the risk of obesity: defining the role of weight loss drugs. Pharmacotherapy 2013; 33: 1308-1321.
168. [No authors listed]. Topiramate+phentermine. An excessively dangerous appetite-suppressant combination. Prescrire Int 2013; 22: 61-64.
169. Toussaint B. First do no harm wanti-obesity and other drugs. BMJ 2013; 346: f3026.